-
公开(公告)号：US11702468B2
公开(公告)日：2023-07-18
申请号：US16554510
申请日：2019-08-28
Applicant: UCB Pharma, S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
IPC: G01N33/68 , G01N33/50 , G01N33/577 , C07K16/22 , C07K14/51 , C07K16/18 , A61K47/64 , C07K14/475
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , G01N33/6854 , C07K2317/76 , G01N33/50 , G01N33/577 , G01N33/68 , G01N33/6863 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
公开(公告)号：US09045537B2
公开(公告)日：2015-06-02
申请号：US14173613
申请日：2014-02-05
Applicant: UCB Pharma S.A.
Inventor： Thomas Allen Ceska , Alistar James Henry , Jiye Shi
IPC: A61K39/395 , C07K16/24 , C07K14/54
CPC classification number: C07K16/244 , C07K14/54 , C07K2299/00 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
Abstract translation: 本发明涉及IL-17A和IL-17F的中和表位和与这些表位结合的抗体。 本发明还涉及抗体分子的治疗用途及其制备方法。
-
公开(公告)号：US09657095B2
公开(公告)日：2017-05-23
申请号：US14662538
申请日：2015-03-19
Applicant: UCB PHARMA S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
IPC: A61K39/00 , A61K39/395 , C07K16/00 , C07K16/18 , C07K16/22 , C12N1/21 , C12N5/10 , C12N5/12 , C12N15/11 , C12N15/13 , C12N15/63 , C07K14/51 , A61K47/48 , C07K14/475 , G01N33/68
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , C07K2317/76 , G01N33/6854 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
4.发明授权Antibodies specific for sclerostin and methods for increasing bone mineralization 有权针对硬皮蛋白的特异性抗体和增加骨矿化的方法公开(公告)号：US09011856B2
公开(公告)日：2015-04-21
申请号：US13670259
申请日：2012-11-06
Applicant: UCB Pharma S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
IPC: A61K39/395 , C07K16/18 , G01N33/53 , C07K16/22 , C07K14/51
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , C07K2317/76 , G01N33/6854 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
Abstract translation: 提供了与特异性结合TGF-β结合蛋白的抗体相关的组合物和方法。 这些方法和组合物涉及通过干扰TGF-β结合蛋白质硬化蛋白和TGF-β超家族成员，特别是骨形态发生蛋白之间的相互作用来改变骨矿物质密度。 增加骨矿物质密度在低骨矿物质密度代表骨质减少症，骨质疏松症和骨折等疾病和病症中具有应用价值。
-
Patent Agency Ranking
公开(公告)号：US08992911B2
公开(公告)日：2015-03-31
申请号：US13670240
申请日：2012-11-06
Applicant: UCB Pharma S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , C07K2317/76 , G01N33/6854 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
公开(公告)号：US20180072801A1
公开(公告)日：2018-03-15
申请号：US15492782
申请日：2017-04-20
Applicant: UCB PHARMA, S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , C07K2317/76 , G01N33/6854 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
公开(公告)号：US20150315272A1
公开(公告)日：2015-11-05
申请号：US14695677
申请日：2015-06-29
Applicant: UCB Pharma S.A.
Inventor： Thomas Allen Ceska , Alistar James Henry , Jiye Shi
IPC: C07K16/24
CPC classification number: C07K16/244 , C07K14/54 , C07K2299/00 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
Abstract translation: 本发明涉及IL-17A和IL-17F的中和表位和与这些表位结合的抗体。 本发明还涉及抗体分子的治疗用途及其制备方法。
-
公开(公告)号：US20240209075A1
公开(公告)日：2024-06-27
申请号：US18333425
申请日：2023-06-12
Applicant: UCB PHARMA S.A.
Inventor： David G. Winkler , Jiye Shi , John Latham
IPC: C07K16/22 , A61K47/64 , C07K14/475 , C07K14/51 , C07K16/18 , G01N33/50 , G01N33/577 , G01N33/68
CPC classification number: C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , G01N33/6854 , C07K2317/76 , G01N33/50 , G01N33/577 , G01N33/68 , G01N33/6863 , G01N2333/4704
Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
公开(公告)号：US20140193403A1
公开(公告)日：2014-07-10
申请号：US14173613
申请日：2014-02-05
Applicant: UCB Pharma S.A.
Inventor： Thomas Allen Ceska , Alistar James Henry , Jiye Shi
IPC: C07K16/24
CPC classification number: C07K16/244 , C07K14/54 , C07K2299/00 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
Abstract translation: 本发明涉及IL-17A和IL-17F的中和表位和与这些表位结合的抗体。 本发明还涉及抗体分子的治疗用途及其制备方法。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.032 seconds)
